Skip to main content
Fig. 3 | Journal of Experimental & Clinical Cancer Research

Fig. 3

From: Intrabodies targeting human papillomavirus 16 E6 and E7 oncoproteins for therapy of established HPV-associated tumors

Fig. 3

Antitumor therapeutic effect of the anti-16E6 scFvI7nuc on C3 tumors. The scatter plot shows the volume of C3 tumors raised in C57/BL6 mice treated with scFvI7nuc (I7nuc) or the unspecific scFvR4nuc (R4nuc). Each point represents the mean volume ± SD of 4 different mice, measured by caliper every 3–4 days. T is the time point in weeks after tumor cell challenge. At the end point (T4), differences are statistically significant (p = 0.0005) by two-tailed Student’s t-test. Two-way repeated measures ANOVA analysis showed p = 0.017 for treatment and p = 0.0001 for linear trend. Data were expressed as means ± standard deviations (SD). Of note, the tumor volume of R4nuc mice had an unexpected increase in the last 3 days prior to the measurement at T4. Despite mice were in good health, tumor burden exceeded the size allowed by our internal ethics and all mice were immediately sacrificed

Back to article page